See more : Invesco Asia Trust plc (IAT.L) Income Statement Analysis – Financial Results
Complete financial analysis of BridgeBio Pharma, Inc. (BBIO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of BridgeBio Pharma, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- PS Business Parks, Inc. (PSB-PX) Income Statement Analysis – Financial Results
- XD Inc. (XDNCF) Income Statement Analysis – Financial Results
- Omnitek Engineering Corp. (OMTK) Income Statement Analysis – Financial Results
- DistIT AB (publ) (DIST.ST) Income Statement Analysis – Financial Results
- Mitesco, Inc. (MITI) Income Statement Analysis – Financial Results
BridgeBio Pharma, Inc. (BBIO)
About BridgeBio Pharma, Inc.
BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 30 development programs that include product candidates ranging from early discovery to late-stage development. Its products in development programs include AG10 and BBP-265, a small molecule stabilizer of transthyretin, or TTR that is in Phase 3 clinical trial for the treatment of TTR amyloidosis-cardiomyopathy, or ATTR-CM; BBP-831, a small molecule selective FGFR1-3 inhibitor, which is Phase 2 clinical trial to treat achondroplasia in pediatric patients; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 2 proof-of-concept clinical trial for Autosomal Dominant Hypocalcemia Type 1, or ADH1; and BBP-711 for the treatment of hyperoxaluria, as well as patients suffering from recurrent kidney stones. In addition, it engages in developing products for Mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and The Regents of the University of California; Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|
| Revenue | 9.30M | 77.65M | 69.72M | 8.25M | 40.56M | 0.00 | 0.00 |
| Cost of Revenue | 2.45M | 3.43M | 3.11M | 3.09M | 2.50M | 0.00 | 260.00K |
| Gross Profit | 6.86M | 74.21M | 66.60M | 5.16M | 38.06M | 0.00 | -260.00K |
| Gross Profit Ratio | 73.71% | 95.58% | 95.53% | 62.57% | 93.84% | 0.00% | 0.00% |
| Research & Development | 455.71M | 402.90M | 454.14M | 337.05M | 209.95M | 140.07M | 30.56M |
| General & Administrative | 0.00 | 0.00 | 0.00 | 145.68M | 94.35M | 43.59M | 13.30M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 150.59M | 143.19M | 192.21M | 145.68M | 94.35M | 43.59M | 13.30M |
| Other Expenses | 7.93M | 100.45M | 35.82M | 1.63M | -1.21M | -1.29M | 0.00 |
| Operating Expenses | 614.23M | 546.09M | 646.35M | 482.73M | 304.30M | 183.66M | 43.86M |
| Cost & Expenses | 616.67M | 546.09M | 646.35M | 482.73M | 306.80M | 183.66M | 43.86M |
| Interest Income | 18.04M | 7.54M | 1.13M | 4.02M | 8.92M | 2.00M | 39.00K |
| Interest Expense | 81.29M | 80.44M | 46.78M | 36.66M | 8.77M | 2.55M | 13.00K |
| Depreciation & Amortization | 6.49M | 6.77M | 5.84M | 3.09M | 859.00K | 245.00K | 260.00K |
| EBITDA | -565.47M | -397.44M | -533.83M | -465.75M | -279.82M | -183.42M | -43.56M |
| EBITDA Ratio | -6,078.34% | -455.49% | -774.11% | -5,683.51% | -688.87% | 0.00% | 0.00% |
| Operating Income | -607.37M | -471.87M | -579.75M | -474.48M | -266.24M | -183.66M | -43.86M |
| Operating Income Ratio | -6,528.75% | -607.71% | -831.58% | -5,751.99% | -656.41% | 0.00% | 0.00% |
| Total Other Income/Expenses | -45.88M | 27.55M | -9.82M | -31.01M | -22.35M | 14.21M | 26.00K |
| Income Before Tax | -653.25M | -484.65M | -586.45M | -505.49M | -288.59M | -169.45M | -43.83M |
| Income Before Tax Ratio | -7,021.94% | -624.17% | -841.20% | -6,127.87% | -711.50% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 9.31M | 52.84M | -21.56M | -28.15M | 16.76M | -13.49M |
| Net Income | -643.20M | -493.96M | -639.30M | -483.93M | -260.44M | -130.75M | -30.57M |
| Net Income Ratio | -6,913.92% | -636.16% | -917.00% | -5,866.47% | -642.10% | 0.00% | 0.00% |
| EPS | -3.95 | -3.35 | -4.43 | -4.10 | -2.48 | -1.42 | -0.33 |
| EPS Diluted | -3.95 | -3.35 | -4.43 | -4.10 | -2.48 | -1.42 | -0.33 |
| Weighted Avg Shares Out | 162.79M | 147.47M | 144.36M | 118.00M | 105.10M | 92.33M | 92.33M |
| Weighted Avg Shares Out (Dil) | 162.79M | 147.47M | 144.36M | 118.00M | 105.10M | 92.33M | 92.33M |
Unnatural Products Announces BridgeBio Exercises Option to License Macrocyclic Therapeutics for Development in Rare Diseases and Oncology
BridgeBio Stock Up on FDA Approval of Cardiovascular Drug
FDA Approves BridgeBio Pharma's Drug For Rare Heart Disease, Poised To Challenge Pfizer In Lucrative Yet Competitive Market
BridgeBio: Next Chapter Begins After Attruby Approval
US FDA approves BridgeBio's drug for rare heart condition
Attruby™ (acoramidis), a Near Complete TTR Stabilizer (≥90%), approved by FDA to Reduce Cardiovascular Death and Cardiovascular-related Hospitalization in ATTR-CM Patients
BridgeBio Pharma's Acoramidis Shows Competitive Edge Against Pfizer's Tafamidisa In Lucrative But Competitive ATTR-CM Market
Open-Label Extension Data Confirms Sustained Benefit of Acoramidis on Cardiovascular Outcomes, Including Statistically Significant Reduction in ACM Within 36 Months
BridgeBio Pharma Announces Publication in the New England Journal of Medicine of Phase 2 PROPEL 2 Study of Infigratinib for Children Living with Achondroplasia
BridgeBio: 2 Weeks Until Major Drug Approval Catalyst - A Buy, With Caveats
Source: https://incomestatements.info
Category: Stock Reports